STUDIES ON SOLID DISPERSIONS OF LEFLUNOMIDE by PR, MAHAPARALE & VP, THORAT
Vol 13, Issue 6, 2020
Online - 2455-3891 
Print - 0974-2441
STUDIES ON SOLID DISPERSIONS OF LEFLUNOMIDE
MAHAPARALE PR1*, THORAT VP2
1Department of Pharmaceutics, Government College of Pharmacy, Aurangabad, Maharashtra, India. 2Department of Pharmaceutics, 
Siddhi College of Pharmacy, Chikhali, Pune, Maharashtra, India. Email: pareshmahaparale@gmail.com
Received: 17 December 2018, Revised: 31 January 2020 Accepted: 11 April 2020
ABSTRACT
Objective: Leflunomide is a nonsteroidal anti-inflammatory drug, which is poorly water soluble. In the present study, attempt has been made to 
prepare and characterize solid dispersions of leflunomide to increase the solubility of drug.
Methods: In preparation of solid dispersion of leflunomide, different polymers such as polyethylene glycol (PEG) 4000, PEG 6000, Poloxamer 188, and 
Poloxamer 407 were used. The effects of several variables such as type of carrier used, drug: carrier ratios, and method of preparation were studied. 
The evaluation of solid dispersions was done by solubility study, dissolution study, and X-ray diffractometry.
Results: Improvement in dissolution of the drug was observed in all solid dispersions as compared to pure drug alone. Solid dispersions prepared 
using Poloxamer 188 showed fastest in vitro drug release. Solid dispersions prepared using solvent evaporation method showed relatively faster 
drug release than melt evaporation method. X-ray diffraction patterns indicated reduced crystallinity of drug particles, which suggest a mechanism of 
enhanced solubility and dissolution of drug in solid dispersion systems.
Conclusions: The study indicated that solid dispersion by solvent evaporation can successfully be further explored and employed to improve solubility 
and dissolution characteristics of poorly soluble drugs.
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INTRODUCTION
The recent advent of high throughput screening of potential therapeutic 
agents has given rise to number of poorly soluble drug candidates. The 
formulation of poorly soluble compounds in oral delivery presents one 
of the most frequent and greatest challenges to formulation scientists 
in the pharmaceutical industry. Drugs with low aqueous solubility have 
low dissolution rates and suffer from oral bioavailability problems. 
Many methods such as solubilization in surfactant systems, formation 
of water soluble complexes, use of prodrug, and salt formation approach 
have been reported for increasing solubility, dissolution, and, in turn, 
bioavailability of drugs. The solid dispersion is defined as dispersion 
of one or more active ingredients in an inert carrier matrix at solid 
state prepared by the melting (fusion), solvent evaporation, or melting-
solvent method [1-3]. Leflunomide is a nonsteroidal anti-inflammatory 
drug, which is poorly water soluble.
MATERIALS AND METHODS
Materials
Leflunomide (Alembic Pharmaceuticals Ltd., Baroda) and various 
carriers such as polyethylene glycol (PEG) 4000, PEG 6000 (Qualigens 
Fine Chemicals, Mumbai), Poloxamer 188, and Poloxamer 407 (BASF, 
Germany) were used. All other chemicals and reagents were of 
analytical grade.
Methods
Preparation of solid dispersions
Solid dispersions of leflunomide were prepared by the following two 
methods.
Solvent evaporation method
Leflunomide and each of water-soluble carriers such as PEG 4000, 
PEG-6000, Poloxamer-188, and Poloxamer-407 were accurately 
weighed separately, transferred into a beaker, and dissolved in a 
sufficient quantity of methanol. Subsequently, methanol was evaporated 
in vacuum evaporator and resulting solid dispersions were stored for 
24 h in a desiccator to remove traces of solvent. Finally, the resultant 
mass was triturated in glass mortar and passed through sieve no. 44. 
The resulting solid dispersions were stored in tightly-closed containers 
until further use [4,11].
Melt evaporation method
Leflunomide and each of water-soluble carriers such as PEG 4000, 
PEG-6000, Poloxamer-188, and Poloxamer-407 were accurately weighed 
separately in porcelain dish and heated to melt. The drug was added to a 
molten mass of polymers with vigorous stirring. Resulting solid dispersions 
were stored in a desiccator for 24 h. The resultant mass was triturated 
in a glass mortar and passed through sieve no. 44. The resulting solid 
dispersions were stored in tight-closed containers until further use [4,5].
Evaluation of solid dispersions
Drug content estimation
The percentage drug content in solid dispersions was estimated 
by dissolving quantities of solid dispersions equivalent to 10 mg of 
leflunomide in 100 ml of methanol. These solutions were further diluted 
with distilled water and UV absorbance was recorded at 259.5 nm [6,7].
Saturation solubility study
Solubility study was performed according to the method reported by 
Higuchi and Connors [3].
X-ray diffraction (XRD) study of solid dispersions
XRD patterns of the selected solid dispersions were compared with 
that of the plain leflunomide. This was done by measuring the 2ø in the 
range of 4–50° with reproducibility of ±0.001° on X-ray diffractometer 
(Philips). The XRD patterns were recorded automatically using rate 
meter with time constant of 2 × 102 pulse/s and with the scanning 
speed of 2° (2ø)/min.
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Table 1: Comparison of various parameters for leflunomide solid dispersion systems
System % drug content Solubility (gm/100 ml) T90 (min)
SE ME SE ME SE ME
LF (alone) - 0.0024 >90
LF:PEG 4000 (1:3) 98.80±0.91 99.86±0.79 0.0098 0.0092 >90 >90
LF:PEG 4000 (1:5) 98.01±0.46 96.96±0.46 0.016 0.016 >90 > 90
LF:PEG 6000 (1:3) 96.38±0.65 97.73±0.72 0.015 0.012 >90 >90
LF:PEG 6000 (1:5) 98.32±1.12 96.89±0.64 0.023 0.018 29 54
LF:P188 (1:3) 95.52±1.65 98.29±1.21 0.032 0.028 29 54
LF:P188 (1:5) 98.28±2.09 98.80±1.21 0.052 0.046 7 8
LF:P407 (1:3) 96.69±2.09 98.54±0.46 0.024 0.021 57 90
LF:P407 (1:5) 97.57±1.65 98.12±1.21 0.038 0.032 22 71
LF:PEG 4000 (1:5) PM 96.52±1.88 97.82±0.96 0.0072 0.0065 >90
LF:PEG 6000 (1:5) PM 98.32±1.92 98.22±1.12 0.01 0.0093 >90
LF:P407 (1:5) PM 97.52±1.25 96.95±1.40 0.018 0.018 > 90
LF:P188 (1:5) PM 98.42±0.98 97.25±1.02 0.028±1.62 0.025±1.08 68
*LF: Leflunomide, P188: Poloxamer 188, P407: Poloxamer 407, SE: Solvent evaporation method, ME: Melt evaporation method, PM: Physical mixture
Fig. 2: Effect of carrier ratio on dissolution profile of leflunomide 
solid dispersion Fig. 3: Effect of carrier type on dissolution profile of leflunomide 
solid dispersion
Dissolution study of solid dispersions
Solid dispersions equivalent to 20 mg of leflunomide were filled in 
hard gelatin capsule by the hand filling method. Dissolution study was 
carried out using USP XXII six-station programmable dissolution test 
Type II apparatus (Veego). Dissolution study was carried out in 900 ml 
of 0.1 N HCl at 37 ± 0.5°C at 50 RPM. The T90 (time required for 90% 
dissolution of the drug) (Table 1) of various solid dispersions was 
calculated [8-10,12].
RESULTS AND DISCUSSION
Evaluation of solid dispersions
Drug content estimation
The percentage drug content of all solid dispersions of leflunomide 
was between 95.52% and 99.86% (Table 1). Standard deviation “<3” 
indicates the uniform distribution of drugs in various solid dispersions.
Saturation solubility study
All solid dispersions showed enhancement in the solubility as compared 
to pure drug alone (Table 1). The drug: carrier ratio (1:5) showed 
higher solubility in all solid dispersions. This may be due to the higher 
proportion of hydrophilic carriers present in solid dispersions. The drug 
gets uniformly dispersed in water-soluble carriers. Hence, as soluble 
carrier dissolves, the dispersed drug also gets exposed to an aqueous 
environment as very fine particles and solubility gets increased. 
Enhancement in solubility was observed in the following order,
Poloxamer 188>Poloxamer 407>PEG 6000>PEG 4000.
XRD study of solid dispersions
Dissolution properties of drug particles are greatly affected by the 
extent of crystallinity present in solid dispersion. An amorphous or the 
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metastable form dissolves faster because of associated higher levels 
of internal energy and greater molecular mobility. These together 
enhance the thermodynamic properties of these forms as compared to 
crystalline state. XRD studies were performed to reveal the crystallinity 
of pure leflunomide, its dispersion with Poloxamer 188 (1:5) and 
pure Poloxamer188 (Fig. 1). Many broad peaks of low intensity were 
observed in diffraction patterns, which indicate microcrystalline nature 
of the drug. The XRD pattern of Poloxamer 188 showed diffraction peaks 
of very low intensity, which confirmed the amorphous nature. The 
XRD pattern for solid dispersions prepared with Poloxamer 188 (1:5), 
however, was characterized by the absence of diffraction peaks of the 
drug, suggesting conversion of microcrystalline form of the drug to an 
amorphous state [17-20].
Dissolution study of solid dispersions
Solid dispersions of drugs showed better dissolution performance as 
compared to pure drug alone. After 1.5 h, release of the drug was found 
to be 25.01%. All solid dispersions of drug showed 68–100% release 
of drug in <1.5 h. This may be attributed to improved wettability of the 
drug particles, significant reduction in particle size of the drug during 
formation of solid dispersions, and higher intrinsic dissolution rate of 
selected soluble carriers, which can pull insoluble but finely mixed drug 
particles into the bulk of the dissolution medium [14-16,21].
Effect of carrier ratio on dissolution rate of leflunomide from 
different solid dispersions
Two different drug: carrier ratios (1:3 and 1:5) were selected to assess 
the effect of the weight fraction of carrier on the release profile of 
drug from solid dispersions (Fig. 2). The dissolution of drug from solid 
dispersions prepared using a higher weight fraction of carrier was 
found to be more; this may be attributed to the molecular and colloidal 
dispersion of the drug in those carrier matrixes.
Effect of carrier type on dissolution rate of leflunomide from 
different solid dispersions
Solid dispersions prepared by both solvent evaporation and melt 
evaporation method showed improved dissolution profiles of a drug 
(Fig. 3). Enhancement in the dissolution profile of the drug was found 
to be of Poloxamer 188>Poloxamer 407>PEG 6000>PEG 4000. The 
increase in dissolution of solid dispersion with Poloxamer 188 may be 
due to high HLB value (HLB 29). Poloxamer 407 HLB value is 21.
Effect of preparation method on dissolution profiles of leflunomide 
from different solid dispersions
Solid dispersions prepared by solvent evaporation method showed 
slightly faster drug release as compared to solid dispersions obtained 
with the melted evaporation method (Fig. 4). In solvent evaporation 
method, both drug and polymer are dissolved in a common solvent 
because of that both may be present in molecular state. When solvent 
is evaporated, drug may get molecularly dispersed in hydrophilic 
carrier matrix. In melt evaporation method, solution of drug is added 
with stirring to melt mass of polymer, which is at a higher temperature 
than drug solution. At that temperature, solvent gets evaporated out 
and some of the drug may precipitate out, and hence, total molecular 
dispersion may not be achieved as that of solvent evaporation method.
Effect of carrier type on dissolution rate of leflunomide from 
physical mixture
Dissolution of drugs from all physical mixtures was found to be more 
as compared to pure drug (Fig. 5). This may be due to hydrophilicity 
of carriers. Dissolution of drug from solid dispersion was found to be 
more than from physical mixture (Fig. 6). This may be due to molecular 
dispersion of the drug in hydrophilic carriers in solid dispersion than 
physical dispersion only.
CONCLUSIONS
From the study on solid dispersions of leflunomide, it was found that,
•	 Enhancement in solubility and dissolution of solid dispersions is in the 
following order, Poloxamer 188>Poloxamer 407>PEG 6000>PEG 4000
•	 Solid dispersions prepared by both solvent evaporation and melt 
evaporation method showed significant improvement in dissolution 
profiles
•	 The dissolution rate for all solid dispersions increased with 
increasing concentration of carriers
•	 Method of preparation of solid dispersions affected the dissolution 
profile of leflunomide. For the same carrier employed, solid 
dispersions prepared by solvent evaporation showed more 
dissolution than those prepared by melting evaporation method
Fig. 4: Effect of preparation method on dissolution profile of leflunomide solid dispersion
Fig. 5: Effect of carrier type on dissolution rate of leflunomide 
from physical mixture
Fig. 6: Comparative dissolution profile of leflunomide from solid 
dispersion and physical mixture
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•	 The enhanced dissolution rate with Poloxamer may be attributed 
to surfactant activity, which facilitates wetting and subsequent 
solubilization of the drug. Poloxamer 188 has high HLB value 
(HLB 29). Hence, it has a greater tendency to solubilize in water.
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